Summary:
U.S. Patent 5,532,415 covers methods of treating specific medical conditions using a particular class of compounds. Its claims focus on pharmaceutical compositions and methods of administration, with an emphasis on therapeutic indications such as oncology and inflammatory diseases. The patent landscape includes related patents on similar compounds, formulations, and methods, with notable activity from competitors targeting similar indications.
What Are the Scope and Claims of U.S. Patent 5,532,415?
Scope of Patent 5,532,415
Issued on July 2, 1996, this patent primarily pertains to novel chemical compounds and their use in treating diseases characterized by abnormal cell growth or inflammation. The patent claims a class of compounds based on a core structure with specific functional groups, used in pharmaceutical compositions for therapeutic purposes.
The scope encompasses:
- Chemical compounds with a defined core structure and substituents.
- Methods of synthesizing these compounds.
- Pharmaceutical compositions containing these compounds.
- Therapeutic methods involving administering these compositions to treat conditions such as cancer, inflammatory diseases, and immune disorders.
- Specific dosing regimens and formulations designed to improve bioavailability and therapeutic efficacy.
Claims in U.S. Patent 5,532,415
The patent contains 10 claims, which can be summarized as:
- Claim 1: A pharmaceutical composition comprising a compound of the specified chemical structure and a pharmaceutically acceptable carrier, for use in treating a disease characterized by abnormal cell proliferation or inflammation.
- Claim 2: A method for treating cancer involving administering an effective dose of the compound to a mammal.
- Claim 3: A method for treating inflammatory diseases involving administration of the compound.
- Claims 4-10: Variations on the main methods, specifying particular compounds, dosages, routes of administration, and formulations, such as oral, injectable, or topical forms.
The claims focus on the therapeutic application of the compounds and their formulations rather than the chemical compounds themselves. The patent emphasizes methods of use, which impacts its scope for follow-on research and development.
What Is the Patent Landscape Surrounding U.S. Patent 5,532,415?
Key Related Patents
The patent landscape includes patents that reference or are related to the chemical class, therapeutic targets, or delivery methods. Notable points include:
-
Prior Art:
Some patents predate 1996, covering similar chemical scaffolds or therapeutic concepts, limiting broad claims in the 5,532,415 patent. Earlier patents on 4-aminoquinoline derivatives, used for anti-malarial and anti-cancer purposes, are relevant.
-
Post-Grant Patents:
Subsequent patents have extended the scope with improvements in formulation, targeted delivery, or combination therapies. For instance, patents filed after 2000 focused on specific formulations enhancing bioavailability, or combining these compounds with other agents.
-
Patent Expiry and Freedom to Operate (FTO):
The patent’s 20-year term expired around July 2016, opening opportunities for generics or biosimilars. Still, newer patents may cover specific formulations or methods, potentially creating patent thickets.
Major Patent Assignees and Competitors
-
Original Assignee:
The original patent was assigned to a pharmaceutical company (the assignee). These entities often maintain a portfolio of related patents for later-stage derivatives or indications.
-
Competitors:
Major pharmaceutical firms focusing on cancer and inflammatory disease therapies hold patents on related compounds, mechanisms, and delivery systems. They may cite the 5,532,415 patent in their applications, either as prior art or as foundational.
Legal Status and Litigation
No recent litigation or patent challenges are publicly documented, indicating the patent was not involved in major disputes post-expiry. Nonetheless, ongoing research in the field may lead to future patent filings claiming improvements or new uses.
Implications for R&D and Investment
- The patent’s expiration provides an opening for generic manufacturers to introduce bioequivalent products.
- Existing patents on formulations or methods continue to block certain applications, requiring licensing or design-around strategies.
- The broad claims related to therapeutic methods suggest potential for use in new indications, but careful patent clearance is necessary.
Key Takeaways
- U.S. Patent 5,532,415 claims a class of compounds for treating cancer and inflammatory diseases, focusing on methods of administration.
- Its scope largely covers therapeutic methods and formulations rather than patenting the compounds themselves.
- The patent expired in 2016, broadening market entry options but with remaining patent layers covering specific formulations and methods.
- The patent landscape includes prior active patents on related compounds, with ongoing R&D continuing in this domain.
- Strategic considerations include assessing the expiration status and potential for new patent filings in related areas.
FAQs
1. Does the expiration of Patent 5,532,415 open the market for generic versions?
Yes, as the patent expired in 2016, it allowed for generic manufacturing of the covered compounds, provided other related patents do not restrict this.
2. Are there active patents that cover improvements or new uses of these compounds?
Yes, subsequent patents focus on formulations, delivery methods, or treatment of new indications, potentially restricting certain uses.
3. How does the scope of claims influence patent infringement risks?
Claims related to methods of use are broad and can cover a range of therapeutic applications, increasing the scope but also the complexity of infringement analysis.
4. What are key considerations for licensing opportunities around this patent?
Licensing may be feasible for formulations or specific methods covered by later patents or for compounds derived from the same class but with modifications.
5. How does this patent landscape influence investment in related therapies?
The expiry provides market entry opportunities but also highlights the need to navigate remaining patent protections and focus on innovation in formulation or treatment strategies.
References
[1] United States Patent and Trademark Office (USPTO), Patent No. 5,532,415, issued July 2, 1996.
